National Beverage Corp. vs Stryker Corporation — how do they compare? National Beverage Corp. trades at $30.88 (market cap $2.77B), while Stryker Corporation trades at $276.39 (market cap $105.64B). The key difference: Stryker Corporation is far larger — about 38.1× National Beverage Corp.'s market cap, and Stryker Corporation pays a 1.28% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Stryker Corporation for 20 Days on average.
| FIZZ | SYK | |
|---|---|---|
Market Cap | $2.77B | $105.64B |
Volume | 413,496 | 1,918,844 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $388.35 |
52-Week Low | $29.20 | $269.75 |
Typical Hold Time | 33 Days | 20 Days |
Enterprise Value | $2.72B | $117.10B |
Dividend Yield | — | 1.28% |
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals from moving averages. The company reported flat revenue of $1.2B in 2025 but maintained strong profitability with 36.2% gross margins and 40.1% ROE. Recent Q1 2027 results showed the first year-over-year revenue growth since Q1 2026, though margins compressed to 35% and EPS declined to $0.50. Analyst sentiment is cautious with 50% sell ratings amid concerns about stalled growth and margin pressure from input costs.
The outlook remains challenging with LaCroix volumes declining for four consecutive years and Trump tariffs impacting profitability. While valuation multiples appear reasonable (P/E 15.9, EV/EBITDA 11.3), the lack of clear growth catalysts and negative cash flow trends present headwinds. The $3.25 special dividend provides shareholder return but reduces equity base, highlighting the company's mature market position.
Stryker (SYK) trades at $275.4, down 1.11% amid a bearish technical signal and negative news flow. The company maintains strong profitability with a 14.43% net margin and a 71% analyst buy rating, but faces headwinds from a manufacturing issue disclosure that triggered an 8.8% stock drop on September 8, 2026. Q3 2026 earnings are due October 29, 2026, following a mixed earnings history with a recent miss in Q1 2026.
The stock presents a divergence between solid fundamentals and near-term sentiment risks. The consensus price target of $368.11 implies significant upside, but ongoing legal investigations and operational challenges pose risks to investor confidence. Earnings growth and resolution of manufacturing issues are critical for sustained recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →